my timesThe Korea Times

ED Delay in inoculation

Listen

AstraZeneca's vaccine put on hold for elderly

South Korea will launch its COVID-19 vaccination program Feb. 26. Under this program, 272,000 patients and people working at geriatric hospitals, nursing homes, rehabilitation centers and other high-risk facilities will get the first batch of AstraZeneca's vaccine in February and March.

However, the health authorities have decided not to vaccinate people aged 65 or older, citing a lack of data on the efficacy of the vaccine developed by the British-Swedish drugmaker and Oxford University. The decision is a step in the right direction to ensure the vaccine's safety and efficacy for the elderly.

It is inevitable for the authorities to put the inoculation of senior citizens on hold, considering the controversy over the vaccine's efficacy flaring up around the world. Germany, France and other European countries have decided not to inoculate people over 65, although the European Medicines Agency (EMA) had already approved the AstraZeneca vaccine for all age groups above 18.

The vaccine appears to have no problems as it was found to be around 60 percent effective in clinical trials. But the problem is that there were insufficient data to show its efficacy for the elderly. For this reason, it is necessary to delay vaccinations for those aged 65 or older. No one can overemphasize the importance of the safety and efficacy of vaccines however urgent it is to check the spread of the coronavirus.

Inoculation of the elderly will be delayed until AstraZeneca submits further data, including the results of Phase 3 clinical trials, possibly in late March. This could also cause a delay in the government's plan to have 70 percent of the population vaccinated by September to build herd immunity here by November.

The authorities had initially planned to administer vaccine shots to 760,000 healthcare workers and the elderly in the first quarter of the year. But about 500,000 elderly people are now excluded from inoculation due to the efficacy issue. If AstraZeneca fails to present further data by March or cannot show the vaccine's efficacy in senior citizens, the country could suffer a further setback to its vaccination timetable.

To better cope with such a problem, the government should make all-out efforts to better protect the elderly from COVID-19 and treat them when they come down with the virus. Most of all, policymakers must do everything they can to keep public confidence in the vaccine program.